The Technology
Allergic diseases, driven primarily by immunoglobulin E (IgE) antibodies, pose a growing global health challenge, affecting millions worldwide. Current treatments, including anti-IgE therapies like omalizumab, are limited by adverse reactions, partial effectiveness, and development of resistance. Our innovative technology introduces a new therapeutic paradigm termed “bind and remove” to facilitate rapid elimination of IgE and to abolish IgE-mediated allergic reactions. We are leveraging engineered “bind and remove” compounds capable to effectively bind, neutralize, and completely remove circulating IgE antibodies. Various innovative compounds have been designed to enhance targeting and ensure efficient and safe clearance of IgE from circulation.
Advantages
- Highly effective neutralization and complete long-term elimination of circulating IgE.
- POC in preclinical models (in vitro and in vivo).
- Avoids resistance and adverse reactions associated with current therapies.
- Versatile delivery strategies ensuring enhanced targeting and elimination.
- Establishing long-lasting therapeutic effect, reducing treatment frequency.
Applications and Opportunities
- Treatment of severe allergic diseases such as Allergic Asthma and Chronic Spontaneous Urticaria.
- Treatment of food allergies.
- Can be used for young children.
- Significant market potential, directly competing with and surpassing current anti-IgE therapies.
- Expanding therapeutic options for patients unresponsive to current medications, creating a new treatment paradigm.
Business Development Contacts